In today’s recent session, 0.46 million shares of the X4 Pharmaceuticals Inc (NASDAQ:XFOR) have been traded, and its beta is 0.40. Most recently the company’s share price was $0.97, and it changed around -$0.02 or -1.70% from the last close, which brings the market valuation of the company to $162.67M. XFOR at last check was trading at a discount to its 52-week high of $2.58, offering almost -165.98% off that amount. The share price’s 52-week low was $0.57, which indicates that the recent value has risen by an impressive 41.24% since then. We note from X4 Pharmaceuticals Inc’s average daily trading volume that its 3-month average coming to 3.40 million.
X4 Pharmaceuticals Inc (NASDAQ:XFOR) trade information
Instantly XFOR has been showing red trend so far today with a performance of -1.70% on intraday trading today. The performance over the last five days has remained in the red territory. The company’s shares are currently up 15.52% year-to-date, but still down -6.87% over the last five days. On the other hand, X4 Pharmaceuticals Inc (NASDAQ:XFOR) is -26.62% down in the 30-day period.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The consensus price target as assigned by Wall Street analysts is $3.67, which translates to bulls needing to increase their stock price by 73.57% from its current value. Analyst projections state that XFOR is forecast to be at a low of $3 and a high of $5.
X4 Pharmaceuticals Inc (XFOR) estimates and forecasts
X4 Pharmaceuticals Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 27.45 percent over the past six months and at a 3.51% annual growth rate that is well below the industry average of 13.10%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 103.00% in revenue this quarter, and will report a decrease of -1,700.00% in the next quarter.
Consensus estimates provided by 6 financial analysts predict the company will bring in an average of $280k in revenue for the current quarter. 7 analysts expect X4 Pharmaceuticals Inc to make $1.73 million in revenue for the quarter ending Sep 2024.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 73.95%.
